Mark A Goldsmith

Mark A Goldsmith sold 10,020 shares of RVMD at $156.12 on 2026-06-16 under pre-arranged 10b5-1 plan; stock up 9.3% in 30d.

Mark A Goldsmith sold 10,020 shares (10.0K shares) of Revolution Medicines, Inc. at $156.12 on 2026-06-16, reducing his holdings from 277,350 to 267,330 shares, a net change of -3.6% of pre-transaction holdings. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2023-05-31, meaning the sale was scheduled rather than discretionary. At the time of sale, RVMD was trading near its 52-week highs ($157.77 current price versus $166.50 52-week high), and the stock has risen 9.3% over the 30 days since the sale. The company reported zero revenue in its latest quarter and a net loss of $453,816,000 for its most recent full fiscal year, indicating ongoing unprofitability. Given the scheduled nature of the trade under a 10b5-1 plan, the sale carries limited signaling value regarding Goldsmith's assessment of the company's prospects.

CFO GOLDSMITH MARK A sold 120.0K RVMD shares at $150.09 (Apr 15); stock now -2.6% from 52-wk high; holder still owns 276.7K shares post-sale

GOLDSMITH sold 120,000 shares (30.2% of pre-transaction holdings) at $150.09 on 2026-04-15, generating $18.0M, while retaining 276.7K shares—a material reduction in exposure to an unprofitable biotech with negative $305.2M net income. The stock has risen sharply: +51.5% over 30 days and +23.6% over 90 days, and currently trades at $148.63, just 2.6% below the 52-week high of $152.54—placing the sale near peak valuation levels. Across his cross-ticker open-market history, GOLDSMITH's 20 prior sells averaged 0.00% well-timed rate at 90 days, indicating they typically occurred before stock gains rather than declines. At this same ticker (RVMD), his recent sale on 2026-03-17 posted a 50.0% 30-day return, and the four March 2026 sales collectively showed mixed near-term outcomes (ranging from +50.0% to -3.4% over 30 days). The timing of this April 15 sale near recent peak levels, combined with the company's unprofitable status and lack of revenue, warrants scrutiny of whether this represents a fundamental reassessment or opportunistic execution at elevated valuations.

CFO Mark A Goldsmith sold 12,871 shares of RVMD at $99.48 on 2026-03-17; stock now at $99.29, -19.4% from 52-week high.

Mark A Goldsmith sold 12,871 shares at $99.48 on 2026-03-17, reducing his holdings by 4.4% to 276,698 shares. The sale occurred near the 52-week high (current price $99.29 is -19.4% from the $123.27 peak), but represents a modest position reduction for an executive at a $19.7B market-cap biotech company. Goldsmith executed five separate sales on 2026-03-02 immediately prior to this transaction, indicating a pattern of ongoing dispositions within a short window. The company is unprofitable with net income of $-305,206,000.00 and zero revenue in the latest quarter, making cash management a relevant context for insider selling activity.

GOLDSMITH sold 36,000 shares (36.0K shares) for $3,644,353.70 ($3.6M) in 13 transactions on 2026-03-02, retaining 64,424 shares (64.4K shares).

GOLDSMITH executed 13 separate sales on 2026-03-02 totaling 36,000 shares at a blended average price of $101.23, reducing his stake by 35.8% from 100,424 shares to 64,424 shares. The multi-tranche structure and price distribution (ranging from $98.17 to $102.20) reflects systematic liquidation across a narrow price band rather than a single opportunistic transaction. His prior sales at RVMD have not demonstrated favorable timing: 0 of 4 measurable prior sells at this ticker posted negative 90-day returns, meaning the stock rose after each prior sale. The company is unprofitable (net income $-305,206,000.00) with zero quarterly revenue, while trading at a $19.9B market cap and currently 18.5% below its 52-week high—a context where large insider dispositions warrant investor attention to both the insider's future plans and the underlying business trajectory.

RVMD insider Mark Goldsmith sells 15,394 shares at $76.82; holds 232,469 shares post-transaction.

Mark Goldsmith sold 15,394 shares of Revolution Medicines at $76.82 on 2025-12-16, reducing his position from 247,863 shares to 232,469 shares. The sale occurred near the 52-week high of $80.06 (-5.1% from peak), and the stock has appreciated 74.5% over the prior 90 days and +7.6% over 30 days. His cross-ticker track record shows 19 prior open-market sells with a 72.73% well-timed rate (measuring whether the stock declined after his sales), though his same-ticker history at RVMD consists of 5 recent sells with only 2 measurable 30-day outcomes (one at +7.9%, one at +21.3%), neither yet showing 90-day results. The company remains unprofitable with $-305.2M net income and zero quarterly revenue, operating in a high-risk pre-commercial stage. The sale represents a 6.2% reduction of his holdings while the stock trades near year-to-date highs.

CFO Mark Goldsmith sells 66,000 shares (49.5% of holdings) for $4,954,962.00 at RVMD on 2025-11-25

Mark A. Goldsmith, CFO, executed 3 separate sales totaling 66,000 shares for $4,954,962.00 at an average price of $75.08 on 2025-11-25, reducing his position by 49.5% to 67,424 shares. This substantial liquidation occurs as the stock trades at its 52-week high of $77.58, following a 33.8% surge over the prior 30 days and a 102.4% rally over 90 days. The company remains deeply unprofitable with a net loss of $-305,206,000.00 on zero revenue in the latest quarter, raising questions about the sustainability of the recent sharp appreciation. Notably, Goldsmith has executed 5 sales at this ticker since October 16, 2025—three within the past week alone—suggesting a pattern of consistent liquidation activity during a period of elevated stock valuation.

RVMD insider GOLDSMITH MARK A sold 20,000 shares at $70.38 on 2025-11-18; stock now at $69.88, up +88.8% in 90 days.

GOLDSMITH MARK A sold 20,000 shares at $70.38 in mid-November as Revolution Medicines rallied strongly, with the stock up +88.8% over the prior 90 days and trading near its 52-week high of $70.58. His cross-ticker track record shows a 72.73% well-timed rate on prior sells, indicating he has historically sold before price declines; however, his same-ticker history at RVMD is mixed—only 1 of 1 measurable prior sales was well-timed at the 90-day mark. The company remains unprofitable with negative annual revenue growth and a -$305.2M net income, creating fundamental headwinds beneath the recent momentum. The sale reduced his holdings by 7.5%, leaving him still invested with 247.9K shares; given the sharp 90-day advance and near-peak pricing, the timing warrants observation as the rally matures.

RVMD insider GOLDSMITH MARK A sold 20,000 shares ($1.3M) on 2025-11-12 amid 36.7% 30-day rally; 2 of 2 measurable prior RVMD sells preceded declines

GOLDSMITH sold 20,000 shares at $65.07 on 2025-11-12, reducing his holdings from 267.9K to 247.9K shares (-7.5%). This sale occurred immediately after a sharp 36.7% 30-day price gain and during a period when the stock has reached its 52-week high ($67.75). His prior trade history at RVMD shows 2 of 2 measurable prior sells at the same ticker (2024-11-04 and 2024-11-01) both resulted in negative 90-day returns (-22.7% and -21.7% respectively), suggesting a pattern of selling ahead of stock declines. The company is unprofitable with net income of $-305.2M and zero revenue in its latest quarter, adding fundamental volatility to the technical signal.

RVMD insider GOLDSMITH MARK A sold 30,000 shares at $60.31 on 2025-11-07 ($1.8M); stock currently $65.83. Insider retains 54,498 shares.

GOLDSMITH sold approximately 35.5% of his pre-transaction holdings at $60.31, just 7.8% below the current price of $65.83 and at the 52-week high. His cross-ticker track record shows a 72.73% well-timed sell rate (avg 90d return -15.5%), and at RVMD specifically, both prior measurable sales (2024-11-04 and 2024-11-01) preceded 90-day declines of -22.7% and -21.7% respectively. However, the company faces material headwinds: $0 revenue in the latest quarter, a -$305.2M annual net loss, and -100.0% annual revenue growth. The stock has surged 35.0% over 30 days and 82.8% over 90 days into this sale, raising questions about whether this large position reduction signals confidence in near-term value (the sale price aligns with 52-week highs) or reflects broader concern about fundamental momentum despite recent price strength.

CFO Mark Goldsmith sells 20,000 RVMD shares for $1.1M at blended $52.74; stock near 52-week high after 41.1% 90d gain

Mark Goldsmith sold 2 separate tranches totaling 20,000 shares (20.0K shares) for $1,054,701.00 ($1.1M) at $50.47 and $55.00 on October 16-17, 2025, reducing his holdings by -4.2% to 452.3K shares. The transactions occurred within a window where RVMD stock has gained 41.1% over 90 days and is trading at $54.01, only -10.9% from its 52-week high of $60.60. Goldsmith's same-ticker history at RVMD shows 5 prior sells, all of which were well-timed at the 90-day mark with negative returns following each sale, suggesting a consistent pattern of selling ahead of declines at this specific company. However, the current price action—+24.0% over the past 30 days and +41.1% over 90 days—reflects significant recent momentum that post-dates his prior pattern, making the timing context of this filing more ambiguous than his historical accuracy would suggest.